Investors might want to bet on LeMaitre Vascular (LMAT) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a ...

Financial Data and Key Metrics Changes - In Q2 2024, the company achieved 12% organic sales growth and 44% EPS growth [4][8] - Gross margin increased to 68.9%, up 490 basis points year over year, driven by productivity improvements and higher average selling prices (ASPs) [8] - Operating income rose 52% year over year to $14.4 million, with an operating margin of 26% [9] Business Line Data and Key Metrics Changes - Seven out of twelve product lines posted record sales, with RestoreFlow allografts up 30%, bovine patches up 12%, and shunts up 22% [4] - The Americas saw a 10% increase in sales, while AMEA sales were up 13% [5] - Canada and the UK experienced significant growth, with increases of 33% and 27% respectively, largely due to RestoreFlow [5] Market Data and Key Metrics Changes - The APAC region was the strongest, with a 20% increase in sales, driven by Thailand and Korea [4] - The company has received 14 of the 22 MDR CE Marks it is seeking, with expectations to receive the remaining approvals in 2025 [6] Company Strategy and Development Direction - The company is focusing on expanding its sales force, targeting 155 to 160 representatives by year-end, primarily in North America [5] - There is an ongoing evaluation of direct market opportunities in Europe, including countries like Portugal and Poland [5] - The company aims to leverage its regulatory approvals to capture market share, particularly in Europe where competition has decreased [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for continued healthy sales and profit growth in 2024, with guidance for mid-teens sales growth in the latter half of the year [9] - The company is cautious about future operating margins, indicating a focus on sustainable growth rather than short-term margin maximization [16] Other Important Information - The company ended Q2 2024 with $113 million in cash and securities, reflecting a $4.8 million increase during the quarter [9] - The company is actively pursuing M&A opportunities, with a focus on larger deals as its cash balance grows [22][49] Q&A Session Summary Question: Sales force expansion and its implications - Management discussed the rationale behind expanding the sales force, emphasizing the need to address large territories and drive sales growth [11][12] Question: Operating margins and future potential - Management provided insights into sustainable drivers for operating margins, indicating that maintaining top-line growth while controlling operating expenses is key [15][16] Question: Updates on M&A activities - The acquisitions department is active, seeking targets that align with the company's strategic focus, with an emphasis on larger deals as cash reserves grow [22][49] Question: Pricing strategy for 2025 - Management indicated that pricing decisions for 2025 will be made later in the year, with historical pricing trends suggesting potential for further increases [23][24] Question: Procedural trends in the U.S. and Europe - Management noted positive trends in hospital staffing and procedural volumes, indicating a healthy operating environment [58] Question: ERP implementation status - The company has implemented ERP in the U.S. and is now preparing for rollout in Europe, starting with the UK [60]

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.64%. A quarter ago, it was expected that this medical device maker would post earnings of $0.39 per share when it actually produced earnings of $0.44, delivering a surprise of 12.82%. Over the last four quart ...

Financial Performance - Q2 2024 sales reached $55.8 million, an increase of 11% year-over-year, with 12% organic growth[2] - Gross margin improved to 68.9%, up 490 basis points from 64.0% in Q2 2023[2] - Operating income was $14.4 million, reflecting a 52% increase compared to Q2 2023[2] - Net income for Q2 2024 was $11.8 million, a 46% increase year-over-year[2] - Earnings per diluted share rose to $0.52, up 44% from the previous year[2] - Net sales for the three months ended June 30, 2024, were $55,849,000, representing a 11.5% increase from $50,115,000 for the same period in 2023[12] - Gross profit for the three months ended June 30, 2024, was $38,468,000, up 20% from $32,086,000 in the prior year[12] - Net income for the three months ended June 30, 2024, was $11,826,000, compared to $8,098,000 for the same period in 2023, reflecting a 46.5% increase[12] - EBITDA for the three months ended June 30, 2024, was $16,753,000, a 40% increase from $11,963,000 in the same period last year[14] - Adjusted net sales for the three months ended June 30, 2024, increased by $5,780,000, or 12%, compared to the same period in 2023[15] Guidance and Projections - Guidance for Q3 2024 sales is projected between $52.7 million and $54.7 million, representing a 13% increase[3] - Full year 2024 sales guidance is set at $216.8 million to $220.8 million, also a 13% increase[3] - The company projects net sales for the three months ending September 30, 2024, to be approximately $53,710,000, with an adjusted increase of $6,537,000, or 14%[15] - Operating income for the year ending December 31, 2024, is projected at $51,096,000, reflecting a significant increase from the previous year[15] - The adjusted projected EPS for the year ending December 31, 2024, is $1.86, reflecting a 37% increase from the previous year[16] - The midpoint guidance for EPS for the year ending December 31, 2024, is set at $1.86[16] Dividend Information - The company announced a quarterly dividend of $0.16 per share, payable on August 29, 2024[4] - Cash dividends declared per common share increased to $0.16 for the three months ended June 30, 2024, compared to $0.14 in the same period last year[12] Cash and Expenses - Cash increased by $4.8 million sequentially to $113.1 million[2] - Operating expenses grew by only 6% year-over-year, indicating controlled cost management[2] - The company reported a total operating expense of $24,088,000 for the three months ended June 30, 2024, which is an increase from $22,634,000 in the same period last year[12] Regional Sales - The Americas accounted for 66% of total net sales for the three months ended June 30, 2024, with sales of $36,907,000[13]

BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects mor ...

Company Overview - LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease, which affects over 200 million people globally [3] Financial Results Announcement - The company will release its second quarter 2024 financial results on August 1, 2024, after market close [2] - A conference call is scheduled for 5:00 PM ET on the same day to discuss the results, business highlights, and company outlook [2] Access to Information - Access to the live call is available through online registration, and registrants will receive dial-in information and a PIN [4] - The audio webcast can be accessed live or via replay on the company's investor website [4]

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Following my last report on LeMaitre Vascular, Inc. (NASDAQ:LMAT) in August FY'23, shares have rallied another 45% into the green, along with 1) increased dividends and 2) improving fundamentals. Back then, I valued the stock at ~$85/share, roughly where it trades today. LMAT is a long-term compounder with mouth-watering economics in my view. Management's efforts have produced a 27% CAGR in market value and 18% CAGR in dividend growth since 2011 ...

Investors might want to bet on LeMaitre Vascular (LMAT) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Most Powerful Force Impacting Stock Prices As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. ...

BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00 AM ET at the Marriott Marquis in New York City. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufact ...

Most Powerful Force Impacting Stock Prices LeMaitre Vascular (LMAT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the c ...